U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Non-secretory plasma cell myeloma

MedGen UID:
857719
•Concept ID:
C3898125
•
Neoplastic Process
Synonyms: non-functioning myeloma; non-secreting myeloma; Non-Secretory Multiple Myeloma; non-secretory multiple myeloma; non-secretory myeloma; Non-Secretory Plasma Cell Myeloma; non-secretory plasma cell myeloma
 
Monarch Initiative: MONDO:0004817

Definition

A rare type of multiple myeloma in which the plasma cells synthesize but do not secrete immunoglobulins. As a result, none of the immunoglobulins appear out of the normal range. The symptoms are generally the same with those of immunoglobulin-secreting myeloma; however, the incidence of renal insufficiency is lower in non-secretory myeloma. The diagnosis can be missed because of the absence of monoclonal immunoglobulin in the serum or urine. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVNon-secretory plasma cell myeloma

Professional guidelines

PubMed

Non-secretory multiple myeloma: Diagnosis and management.
Charliński G, Jurczyszyn A
Adv Clin Exp Med 2022 Jan;31(1):95-100. doi: 10.17219/acem/141455. PMID: 34637200
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group
Leukemia 2009 Feb;23(2):215-24. Epub 2008 Nov 20 doi: 10.1038/leu.2008.307. PMID: 19020545
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
International Myeloma Working Group
Br J Haematol 2003 Jun;121(5):749-57. PMID: 12780789

Recent clinical studies

Etiology

Non-secretory multiple myeloma: Diagnosis and management.
Charliński G, Jurczyszyn A
Adv Clin Exp Med 2022 Jan;31(1):95-100. doi: 10.17219/acem/141455. PMID: 34637200
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ; UK NCRI Haemato-oncology Clinical Studies Group
Lancet Oncol 2019 Jan;20(1):57-73. Epub 2018 Dec 14 doi: 10.1016/S1470-2045(18)30687-9. PMID: 30559051Free PMC Article
Non-secretory myeloma: a clinician's guide.
Lonial S, Kaufman JL
Oncology (Williston Park) 2013 Sep;27(9):924-8, 930. PMID: 24282993
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group
Leukemia 2009 Feb;23(2):215-24. Epub 2008 Nov 20 doi: 10.1038/leu.2008.307. PMID: 19020545
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
International Myeloma Working Group
Br J Haematol 2003 Jun;121(5):749-57. PMID: 12780789

Diagnosis

Non-secretory multiple myeloma: Diagnosis and management.
Charliński G, Jurczyszyn A
Adv Clin Exp Med 2022 Jan;31(1):95-100. doi: 10.17219/acem/141455. PMID: 34637200
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ; UK NCRI Haemato-oncology Clinical Studies Group
Lancet Oncol 2019 Jan;20(1):57-73. Epub 2018 Dec 14 doi: 10.1016/S1470-2045(18)30687-9. PMID: 30559051Free PMC Article
Non-secretory myeloma: a clinician's guide.
Lonial S, Kaufman JL
Oncology (Williston Park) 2013 Sep;27(9):924-8, 930. PMID: 24282993
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group
Leukemia 2009 Feb;23(2):215-24. Epub 2008 Nov 20 doi: 10.1038/leu.2008.307. PMID: 19020545
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
International Myeloma Working Group
Br J Haematol 2003 Jun;121(5):749-57. PMID: 12780789

Therapy

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ; UK NCRI Haemato-oncology Clinical Studies Group
Lancet Oncol 2019 Jan;20(1):57-73. Epub 2018 Dec 14 doi: 10.1016/S1470-2045(18)30687-9. PMID: 30559051Free PMC Article
Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.
Heaney JLJ, Campbell JP, Griffin AE, Birtwistle J, Shemar M, Child JA, Gregory WM, Cairns DA, Morgan G, Jackson G, Drayson MT
Br J Haematol 2017 Jul;178(2):220-230. Epub 2017 Jun 1 doi: 10.1111/bjh.14753. PMID: 28573706
Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature.
Sekiguchi Y, Ichikawa K, Wakabayashi M, Sugimoto K, Tomita S, Izumi H, Nakamura N, Sawada T, Ohta Y, Komatsu N, Noguchi M
Int J Clin Exp Pathol 2015;8(8):9609-19. Epub 2015 Aug 1 PMID: 26464727Free PMC Article
Clinical course and prognosis of non-secretory multiple myeloma.
Chawla SS, Kumar SK, Dispenzieri A, Greenberg AJ, Larson DR, Kyle RA, Lacy MQ, Gertz MA, Rajkumar SV
Eur J Haematol 2015 Jul;95(1):57-64. Epub 2015 Jan 21 doi: 10.1111/ejh.12478. PMID: 25382589
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
International Myeloma Working Group
Br J Haematol 2003 Jun;121(5):749-57. PMID: 12780789

Prognosis

Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells.
Mack EKM, Hartmann S, Ross P, Wollmer E, Mann C, Neubauer A, Brendel C, Hoffmann J
Ann Hematol 2022 Apr;101(4):811-824. Epub 2022 Feb 1 doi: 10.1007/s00277-022-04771-5. PMID: 35106639Free PMC Article
Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma.
Migkou M, Avivi I, Gavriatopoulou M, Cohen YC, Fotiou D, Kanellias N, Ziogas D, Eleutherakis-Papaiakovou E, Terpos E, Roussou M, Kastritis E, Dimopoulos MA
Ann Hematol 2020 Jun;99(6):1251-1255. Epub 2020 Apr 19 doi: 10.1007/s00277-020-03984-w. PMID: 32307566
Non-secretory myeloma: a clinician's guide.
Lonial S, Kaufman JL
Oncology (Williston Park) 2013 Sep;27(9):924-8, 930. PMID: 24282993
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group
Leukemia 2009 Feb;23(2):215-24. Epub 2008 Nov 20 doi: 10.1038/leu.2008.307. PMID: 19020545
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
International Myeloma Working Group
Br J Haematol 2003 Jun;121(5):749-57. PMID: 12780789

Clinical prediction guides

Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China.
Sun H, Liu A, Liu L, Wang W, Cai Z, Yan H, Chen L, Gao G, Wang F, Liao A, Chen B, Feng J, Li J, Huang DP, Gao D, Zhang QK, Luo J, Fu R, Du J, Lu J
BMC Cancer 2023 Oct 2;23(1):930. doi: 10.1186/s12885-023-11223-4. PMID: 37784037Free PMC Article
Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells.
Mack EKM, Hartmann S, Ross P, Wollmer E, Mann C, Neubauer A, Brendel C, Hoffmann J
Ann Hematol 2022 Apr;101(4):811-824. Epub 2022 Feb 1 doi: 10.1007/s00277-022-04771-5. PMID: 35106639Free PMC Article
Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry.
Wålinder G, Samuelsson J, Näsman P, Hansson M, Juliusson G, Forsberg K, Svensson R, Linder O, Carlson K, Kristinsson SY, Mellqvist UH, Hveding Blimark C, Turesson I, Nahi H
Eur J Haematol 2020 May;104(5):376-382. Epub 2020 Feb 22 doi: 10.1111/ejh.13351. PMID: 31733147
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ; UK NCRI Haemato-oncology Clinical Studies Group
Lancet Oncol 2019 Jan;20(1):57-73. Epub 2018 Dec 14 doi: 10.1016/S1470-2045(18)30687-9. PMID: 30559051Free PMC Article
Non-secretory myeloma: a clinician's guide.
Lonial S, Kaufman JL
Oncology (Williston Park) 2013 Sep;27(9):924-8, 930. PMID: 24282993

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...